Lilly’s Foundayo shows cardiovascular safety in diabetes trial

Eli Lilly's Phase 3 ACHIEVE-4 trial showed oral GLP-1 Foundayo (orforglipron) met its cardiovascular-safety non-inferiority endpoint versus insulin glargine in 2,749 adults with type 2 diabetes and obesity or overweight. Foundayo reduced A1C by 1.6% versus 1.0% and cut body weight by 8.8% versus a 1.7% gain with insulin glargine at 52 weeks; it was associated with 16% lower MACE-4 risk, although the 95% confidence interval crossed 1.0. Tolerability remains a consideration, with 10.6% discontinuing Foundayo because of adverse events during the minimum 52-week treatment period.

Analysis

The investable read-through is less about incremental diabetes efficacy and more about de-risking an oral incretin franchise that could expand Lilly’s addressable market beyond injection-accepting patients. A daily pill can shift treatment earlier in the disease pathway, potentially displacing basal-insulin intensification and increasing duration of therapy; that matters most for LLY’s 2027-29 revenue mix and supports a higher terminal value than a weight-loss-only framing. The principal competitive pressure is on NVO’s oral semaglutide franchise and on legacy diabetes suppliers with exposure to insulin analogs, including SNY, although biosimilarization limits the latter’s equity sensitivity.

The cardiovascular result is directionally supportive but should not be capitalized as a definitive outcomes advantage: the confidence intervals do not establish superiority, while mortality sub-analyses are vulnerable to low event counts and multiplicity. The market’s next 1-3 month focus should be regulatory-label language, manufacturing scale, net price versus injectable GLP-1s, and discontinuation in commercial populations; tolerability-driven persistence will determine whether oral convenience translates into superior lifetime value. A favorable label without evidence of adequate pill supply would be strategically positive but financially back-end loaded.

Consensus may overstate near-term cannibalization of Lilly’s injectable franchise. Oral access can be incremental if it unlocks primary-care prescribing and earlier-line use, but aggressive payer step edits could force it into lower-priced channels and dilute blended revenue per patient. The thesis is falsified if launch guidance implies materially lower net price, persistence falls below injectable benchmarks, or NVO demonstrates meaningfully better oral efficacy/tolerability in a comparable population.

Key Decisions for Investors

• Maintain or add LLY only on post-result weakness rather than chase an initial headline move; target a 6-18 month position sized for oral-franchise optionality, with risk defined by 2027 revenue guidance and evidence of net-price dilution.
• Initiate a 3-6 month relative-value watch: long LLY / short NVO only if NVO underperforms on oral persistence, payer access, or prescription-trend data. The pair isolates oral-GLP-1 share risk; exit if NVO’s oral product retains a clear efficacy or adherence advantage.
• Avoid a broad short in SNY solely on potential basal-insulin substitution: insulin exposure is not sufficiently concentrated and pricing is already structurally pressured. Reassess only if quarterly diabetes sales show a renewed volume decline beyond current expectations.
• Set alerts for FDA labeling, launch supply commentary, and first commercial discontinuation data. A restrictive cardiovascular claim, delayed capacity ramp, or discontinuation above trial experience would reduce the oral platform’s valuation support and warrants trimming LLY.